Asset Details
Do you wish to reserve the book?
Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events
Do you wish to request the book?
Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events
2024
Overview
Background
Droperidol is a first-generation antipsychotic medication that has been used for various indications in the emergency department (ED); however, its use has been controversial due to reports of QT prolongation and the risk of torsades de pointes (TdP). The aim of the study is to evaluate the safety of droperidol administration in the ED.
Methods
This was a retrospective study, conducted at an academic level I trauma center. System-generated reports were used to identify all droperidol administrations in the ED from the time that droperidol was reintroduced to the institutional formulary on July 1, 2019 through January 31, 2023. The major safety endpoint was a composite of the incidence of QTc interval prolongation, incidence of TdP, ventricular arrhythmia, or hypotension.
Results
A total of 327 administrations of droperidol were identified in 245 patients in the ED. The composite safety endpoint occurred in 30 (9.1%) administrations. None of these events were classified as “probable” or “definite” on the Naranjo adverse drug reaction probability scale. No episodes of TdP or serious ventricular arrhythmia were reported. Higher cumulative droperidol dose and creatinine clearance < 60 mL/min were associated with an increased odds of developing QTc prolongation (OR 1.27 [CI 1.04–1.56]) and (OR 1.01 [CI 1.0-1.02]), respectively.
Conclusions
The study supports the use of low dose droperidol for various indications in the ED. There were no serious adverse events reported that could be directly attributed to droperidol use; however, it is crucial to consider the potential dose dependent impact on QTc prolongation.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Antipsychotic Agents - administration & dosage
/ Antipsychotic Agents - adverse effects
/ Complications and side effects
/ Droperidol - administration & dosage
/ Droperidol - adverse effects
/ Droperidol - therapeutic use
/ Female
/ Humans
/ Long QT Syndrome - chemically induced
/ Male
/ Medicine
/ Nausea
/ Patients
/ Torsades de Pointes - chemically induced
/ Vomiting
We currently cannot retrieve any items related to this title. Kindly check back at a later time.